Abstract
Background: Hyperphosphorylation of tau leads to conformational changes that destabilize microtubules and hinder axonal transport in Alzheimer's disease (AD). However, it remains unknown whether white matter (WM) decline due to AD is associated with specific Tau phosphorylation site(s). Methods: In autosomal dominant AD (ADAD) mutation carriers (MC) and non-carriers (NC) we compared cerebrospinal fluid (CSF) phosphorylation at tau sites (pT217, pT181, pS202, and pT205) and total tau with WM measures, as derived from diffusion tensor imaging (DTI), and cognition. A WM composite metric, derived from a principal component analysis, was used to identify spatial decline seen in ADAD. Results: The WM composite explained over 70% of the variance in MC. WM regions that strongly contributed to the spatial topography were located in callosal and cingulate regions. Loss of integrity within the WM composite was strongly associated with AD progression in MC as defined by the estimated years to onset (EYO) and cognitive decline. A linear regression demonstrated that amyloid, gray matter atrophy and phosphorylation at CSF tau site pT205 each uniquely explained a reduction in the WM composite within MC that was independent of vascular changes (white matter hyperintensities), and age. Hyperphosphorylation of CSF tau at other sites and total tau did not significantly predict WM composite loss. Conclusions: We identified a site-specific relationship between CSF phosphorylated tau and WM decline within MC. The presence of both amyloid deposition and Tau phosphorylation at pT205 were associated with WM composite loss. These findings highlight a primary AD-specific mechanism for WM dysfunction that is tightly coupled to symptom manifestation and cognitive decline.
Original language | English (US) |
---|---|
Article number | 105714 |
Journal | Neurobiology of Disease |
Volume | 168 |
DOIs | |
State | Published - Jun 15 2022 |
Keywords
- ADAD
- CSF
- PCA
- Phosphorylated tau
- White matter
ASJC Scopus subject areas
- Neurology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease. / Strain, Jeremy F.; Barthelemy, Nicolas; Horie, Kanta et al.
In: Neurobiology of Disease, Vol. 168, 105714, 15.06.2022.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease
AU - Strain, Jeremy F.
AU - Barthelemy, Nicolas
AU - Horie, Kanta
AU - Gordon, Brian A.
AU - Kilgore, Collin
AU - Aschenbrenner, Andrew
AU - Cruchaga, Carlos
AU - Xiong, Chengjie
AU - Joseph-Mathurin, Nelly
AU - Hassenstab, Jason
AU - Fagan, Anne M.
AU - Li, Yan
AU - Karch, Celeste M.
AU - Perrin, Richard J.
AU - Berman, Sarah B.
AU - Chhatwal, Jasmeer P.
AU - Graff-Radford, Neill R.
AU - Mori, Hiroshi
AU - Levin, Johannes
AU - Noble, James M.
AU - Allegri, Ricardo
AU - Schofield, Peter R.
AU - Marcus, Daniel S.
AU - Holtzman, David M.
AU - Morris, John C.
AU - Benzinger, Tammie L.S.
AU - McDade, Eric M.
AU - Bateman, Randall J.
AU - Ances, Beau M.
N1 - Funding Information: Data collection and sharing for this project was supported by the Dominantly Inherited Alzheimer's Network (DIAN, UF1AG032438 ) funded by the National Institute on Aging (NIA), the German Center for Neurodegenerative Diseases (DZNE), Raul Carrea Institute for Neurological Research (FLENI), and partial support by the Research and Development Grants for Dementia from Japan Agency for Medical Research and Development , AMED, and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI). The primary contact of DIAN is Dr. Randall J. Bateman. This manuscript has been reviewed by DIAN Study investigators for scientific content and consistency of data interpretation with previous DIAN Study publications. We acknowledge the altruism of the participants and their families and contributions of the DIAN research and support staff at each of the participating sites for their contributions to this study. We acknowledge the financial support of Fred Simmons and Olga Mohan, the Barnes-Jewish Hospital Foundation, the Charles F. and Joanne Knight Alzheimer's Research Initiative, the Hope Center for Neurological Disorders , the Mallinckrodt Institute of Radiology , the Daniel Brennan MD Fund, and the Paula and Rodger O. Riney Fund. Data management and computations were made possible using the facilities of the Washington University Center for High-Performance Computing, and the Central Neuroimaging Data Archive (CNDA)/Neuroimaging Informatics and Analysis Center (NIAC) ( 1P30NS098577 , R01 EB009352 ). J.F.S. is supported in part by BrightFocus Foundation grant A2018817F . N.J.M. is supported in part by the Alzheimer's Association Research Fellowship ( AARFD-20-681815 ). Funding Information: This work would not have been possible without the dedication and contribution from our participants. We additionally thank all of the research centers and affiliated partners that comprise the Dominantly Inherited Alzheimer Network. This research was funded by the National Institutes of Health (NIH: UFAG032438, UL1TR000448, P30NS098577, R01AG052550, R01EB009352, R01NR012907, R01NR012657, R01NR014449, P50AG05681, P01AG003991, P01AG026276, P30NS048056, UL1TR000448, R01AG04343404, and NSF grant DMS1300280), the German Center for Neurodegenerative Diseases (DZNE), the national institute for Health Research (NIHR) Queen Square Dementia Biomedical Research Centre, and the Medical Research Council Dementias Platform UK (MR/L023784/1 and MR/009076/1). There are several inventions that have been filed by WashU for patents, including ?Methods of diagnosing AD with phosphorylation changes?. This intellectual property owned by WashU can be or is licensed and some licensing income may be distributed to Drs. Barthelemy, Bateman, McDade and Sato and other inventors. This intellectual property being licensed by Washington University from C2N and currently being utilized in our research have been reviewed by the Washington University COI and ICOI committees. All co-inventors, including some lab members, Dr. Holtzman, the University, and Dr. Barthelemy, Bateman, McDade and Sato could receive part of the profits from any sales of these tests by C2N, which is in the process of licensing or has licensed some IP from the University. In addition, Dr. Holtzman and the University have a financial investment in C2N, such as stock or ownership interest. There is the potential for Dr. Holtzman and the University to gain or lose value of C2N ownership depending on the results of these studies. Dr. Holtzman also serves on the Scientific Advisory Board for C2N. These activities have been reviewed by Washington University's (WU) Conflicts of Interest Review Committee in accordance with WU's Research Conflicts of Interest Policy and WU's Institutional Conflict of Interest Review Committee in accordance with WU's Institutional Conflict of Interest Policy. Data collection and sharing for this project was supported by the Dominantly Inherited Alzheimer's Network (DIAN, UF1AG032438) funded by the National Institute on Aging (NIA), the German Center for Neurodegenerative Diseases (DZNE), Raul Carrea Institute for Neurological Research (FLENI), and partial support by the Research and Development Grants for Dementia from Japan Agency for Medical Research and Development, AMED, and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI). The primary contact of DIAN is Dr. Randall J. Bateman. This manuscript has been reviewed by DIAN Study investigators for scientific content and consistency of data interpretation with previous DIAN Study publications. We acknowledge the altruism of the participants and their families and contributions of the DIAN research and support staff at each of the participating sites for their contributions to this study. We acknowledge the financial support of Fred Simmons and Olga Mohan, the Barnes-Jewish Hospital Foundation, the Charles F. and Joanne Knight Alzheimer's Research Initiative, the Hope Center for Neurological Disorders, the Mallinckrodt Institute of Radiology, the Daniel Brennan MD Fund, and the Paula and Rodger O. Riney Fund. Data management and computations were made possible using the facilities of the Washington University Center for High-Performance Computing, and the Central Neuroimaging Data Archive (CNDA)/Neuroimaging Informatics and Analysis Center (NIAC) (1P30NS098577, R01 EB009352). J.F.S. is supported in part by BrightFocus Foundation grant A2018817F. N.J.M. is supported in part by the Alzheimer's Association Research Fellowship (AARFD-20-681815). Funding Information: This work would not have been possible without the dedication and contribution from our participants. We additionally thank all of the research centers and affiliated partners that comprise the Dominantly Inherited Alzheimer Network. This research was funded by the National Institutes of Health (NIH: UFAG032438 , UL1TR000448 , P30NS098577 , R01AG052550 , R01EB009352 , R01NR012907 , R01NR012657 , R01NR014449 , P50AG05681 , P01AG003991 , P01AG026276 , P30NS048056 , UL1TR000448 , R01AG04343404 , and NSF grant DMS1300280 ), the German Center for Neurodegenerative Diseases (DZNE) , the national institute for Health Research (NIHR) Queen Square Dementia Biomedical Research Centre , and the Medical Research Council Dementias Platform UK ( MR/L023784/1 and MR/009076/1 ). Publisher Copyright: © 2022
PY - 2022/6/15
Y1 - 2022/6/15
N2 - Background: Hyperphosphorylation of tau leads to conformational changes that destabilize microtubules and hinder axonal transport in Alzheimer's disease (AD). However, it remains unknown whether white matter (WM) decline due to AD is associated with specific Tau phosphorylation site(s). Methods: In autosomal dominant AD (ADAD) mutation carriers (MC) and non-carriers (NC) we compared cerebrospinal fluid (CSF) phosphorylation at tau sites (pT217, pT181, pS202, and pT205) and total tau with WM measures, as derived from diffusion tensor imaging (DTI), and cognition. A WM composite metric, derived from a principal component analysis, was used to identify spatial decline seen in ADAD. Results: The WM composite explained over 70% of the variance in MC. WM regions that strongly contributed to the spatial topography were located in callosal and cingulate regions. Loss of integrity within the WM composite was strongly associated with AD progression in MC as defined by the estimated years to onset (EYO) and cognitive decline. A linear regression demonstrated that amyloid, gray matter atrophy and phosphorylation at CSF tau site pT205 each uniquely explained a reduction in the WM composite within MC that was independent of vascular changes (white matter hyperintensities), and age. Hyperphosphorylation of CSF tau at other sites and total tau did not significantly predict WM composite loss. Conclusions: We identified a site-specific relationship between CSF phosphorylated tau and WM decline within MC. The presence of both amyloid deposition and Tau phosphorylation at pT205 were associated with WM composite loss. These findings highlight a primary AD-specific mechanism for WM dysfunction that is tightly coupled to symptom manifestation and cognitive decline.
AB - Background: Hyperphosphorylation of tau leads to conformational changes that destabilize microtubules and hinder axonal transport in Alzheimer's disease (AD). However, it remains unknown whether white matter (WM) decline due to AD is associated with specific Tau phosphorylation site(s). Methods: In autosomal dominant AD (ADAD) mutation carriers (MC) and non-carriers (NC) we compared cerebrospinal fluid (CSF) phosphorylation at tau sites (pT217, pT181, pS202, and pT205) and total tau with WM measures, as derived from diffusion tensor imaging (DTI), and cognition. A WM composite metric, derived from a principal component analysis, was used to identify spatial decline seen in ADAD. Results: The WM composite explained over 70% of the variance in MC. WM regions that strongly contributed to the spatial topography were located in callosal and cingulate regions. Loss of integrity within the WM composite was strongly associated with AD progression in MC as defined by the estimated years to onset (EYO) and cognitive decline. A linear regression demonstrated that amyloid, gray matter atrophy and phosphorylation at CSF tau site pT205 each uniquely explained a reduction in the WM composite within MC that was independent of vascular changes (white matter hyperintensities), and age. Hyperphosphorylation of CSF tau at other sites and total tau did not significantly predict WM composite loss. Conclusions: We identified a site-specific relationship between CSF phosphorylated tau and WM decline within MC. The presence of both amyloid deposition and Tau phosphorylation at pT205 were associated with WM composite loss. These findings highlight a primary AD-specific mechanism for WM dysfunction that is tightly coupled to symptom manifestation and cognitive decline.
KW - ADAD
KW - CSF
KW - PCA
KW - Phosphorylated tau
KW - White matter
UR - http://www.scopus.com/inward/record.url?scp=85127359599&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127359599&partnerID=8YFLogxK
U2 - 10.1016/j.nbd.2022.105714
DO - 10.1016/j.nbd.2022.105714
M3 - Article
C2 - 35358703
AN - SCOPUS:85127359599
SN - 0969-9961
VL - 168
JO - Neurobiology of Disease
JF - Neurobiology of Disease
M1 - 105714
ER -